In the past week, DNA stock has gone up by 10.99%, with a monthly decline of -43.45% and a quarterly plunge of -23.97%. The volatility ratio for the week is 9.24%, and the volatility levels for the last 30 days are 10.63% for Ginkgo Bioworks Holdings Inc The simple moving average for the last 20 days is -10.92% for DNA stock, with a simple moving average of -31.38% for the last 200 days.
Is It Worth Investing in Ginkgo Bioworks Holdings Inc (NYSE: DNA) Right Now?
The 36-month beta value for DNA is also noteworthy at 1.22. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 1 rating it as “sell.”
The public float for DNA is 36.99M, and at present, short sellers hold a 24.50% of that float. The average trading volume of DNA on March 21, 2025 was 1.70M shares.
DNA) stock’s latest price update
The stock price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) has plunged by -4.14 when compared to previous closing price of 7.48, but the company has seen a 10.99% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-14 that Dublin, March 14, 2025 (GLOBE NEWSWIRE) — The “Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032” report has been added to ResearchAndMarkets.com’s offering. A newly revealed comprehensive overview of the circulating DNA/RNA patent landscape discloses remarkable industry growth projections, with an expected surge from USD 5.32 billion in 2023 to USD 16.4 billion by 2032. The market is advancing at an impressive compound annual growth rate (CAGR) of 13.29%, driven by innovations in nucleic acid-based therapeutics and diagnostics. Patent Landscape Overview The report provides a thorough examination of blood-based biomarkers critical for non-invasive diagnostics in various conditions ranging from cancer to genetic disorders. The increasing number of patents in next-generation sequencing, cancer biomarkers, and therapeutic delivery systems are significantly shaping the industry landscape, propelling advancements in non-invasive diagnostics and personalised medicine. Regional Patent Activity Highlights Insights into the patent activity emphasize the dominance of the United States with over 600 patents, closely pursued by Europe and Asia, with 400 and 250 patents respectively. These regions underscore significant contributions to the industry, each with distinctive advantages in the biotech sector and supportive government initiatives that enhance the competitive position on a global scale. Segmentation Analysis The patent landscape encompasses a myriad of segments, primarily led by the oncology sector with a notable number of filings. Innovations in non-invasive diagnostics and personalised medicine are elucidated, showcasing strategic focus areas for major actors in the field. Furthermore, the in-depth analysis spells out the dynamics within technologies and indications, predicting continued growth and expansion into diverse medical applications. Key Industry Players Prominent market participants such as Nantomics, Genentech Inc., and Novartis AG are pivotal in the development of the circulating DNA/RNA patent landscape. These companies hold substantive patents in detection, analysis, and therapeutic applications of circulating nucleic acids, reinforcing their impact on the overall industry growth and innovation trajectory. Strategic Insights and Future Opportunities The comprehensive analysis of the patent landscape signifies a vibrant and advancing sector, providing strategic insights into industry dynamics and future opportunities. As patents continue to drive the expansion of this domain, stakeholders and industry participants can anticipate new technological frontiers in personalised medicine and non-invasive diagnostic methodologies, ultimately enhancing patient care and healthcare outcomes. This landmark report reflects the propulsive nature of the circulating DNA/RNA sector, offering critical insights that underpin the unfolding narrative of genomic medicine and its expansive potential. Key Attributes:
Analysts’ Opinion of DNA
Raymond James gave a rating of “Mkt Perform” to DNA, setting the target price at $2.50 in the report published on November 14th of the previous year.
DNA Trading at -32.45% from the 50-Day Moving Average
After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.06% of loss for the given period.
Volatility was left at 10.63%, however, over the last 30 days, the volatility rate increased by 9.24%, as shares sank -37.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.45% lower at present.
During the last 5 trading sessions, DNA rose by +10.99%, which changed the moving average for the period of 200-days by -66.08% in comparison to the 20-day moving average, which settled at $8.05. In addition, Ginkgo Bioworks Holdings Inc saw -26.99% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNA starting from Che Austin, who proposed sale 99 shares at the price of $7.40 back on Mar 20 ’25. After this action, Che Austin now owns shares of Ginkgo Bioworks Holdings Inc, valued at $733 using the latest closing price.
Che Austin, the Officer of Ginkgo Bioworks Holdings Inc, proposed sale 99 shares at $7.27 during a trade that took place back on Mar 19 ’25, which means that Che Austin is holding shares at $720 based on the most recent closing price.
Stock Fundamentals for DNA
Current profitability levels for the company are sitting at:
- -2.38 for the present operating margin
- 0.68 for the gross margin
The net margin for Ginkgo Bioworks Holdings Inc stands at -2.41. The total capital return value is set at -0.43. Equity return is now at value -60.34, with -35.96 for asset returns.
Based on Ginkgo Bioworks Holdings Inc (DNA), the company’s capital structure generated 0.38 points at debt to capital in total, while cash flow to debt ratio is standing at -0.73. The debt to equity ratio resting at 0.61. The interest coverage ratio of the stock is -5749.91.
Currently, EBITDA for the company is -484.39 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 1.29. The receivables turnover for the company is 10.39for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.62.
Conclusion
In summary, Ginkgo Bioworks Holdings Inc (DNA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
